There is a fundamental tension at the center of every rapamycin + training protocol. Exercise works, in significant part, by activating mTOR. Rapamycin works by inhibiting mTOR. If you are stacking both, you are pressing the accelerator and the brake at the same time — at least at the molecular level.
This has been a theoretical concern since rapamycin entered the longevity conversation. The first randomized controlled trial to test it directly in humans landed in 2026, and the results are worth reading carefully — not because they are alarming, but because they are specific in ways that matter.
The RAPA-EX-01 Trial: Methodology
Stanfield et al. published the RAPA-EX-01 trial in the Journal of Cachexia, Sarcopenia and Muscle (DOI: 10.1002/jcsm.70274). This was a randomized, double-blind, placebo-controlled design — the gold standard for this kind of question.
Who was in the trial: 40 sedentary adults aged 65–85. This population was chosen specifically because they had the most to gain from an exercise program and the most to lose from any interference with those gains.
The intervention: A 13-week home exercise program combining chair-stand repetitions and cycle ergometer sessions. Alongside the exercise, participants received either weekly oral sirolimus (rapamycin) at 6 mg — a dose at the higher end of what longevity physicians typically prescribe — or a matched placebo.
The primary outcomes measured: Chair-stand test performance (a validated proxy for lower-body functional strength), six-minute walk test (6MWT) distance, grip strength via dynamometer, and subjective fatigue and soreness scores.
What the Results Actually Showed
In the rapamycin arm, participants showed statistically significant blunting of functional gains in the chair-stand test compared to the placebo group. Fewer repetitions completed, less improvement from baseline.
For the 6MWT and grip strength, the rapamycin group trended worse, but these differences did not reach statistical significance — meaning the trial cannot rule out that those differences were due to chance.
On the subjective side, the rapamycin group reported meaningfully higher fatigue and soreness ratings during the training weeks. One participant in the rapamycin arm experienced a serious infection that required medical attention — consistent with rapamycin's known immunosuppressive effects at this dose.
"Blunting" in this context means the rapamycin group still improved from their baseline — they just improved less than the placebo group. This trial did not show that rapamycin eliminated exercise gains. It suggests rapamycin may have reduced the magnitude of those gains in this specific population.
Why This Happens: mTORC1 as the Shared Target
To understand why this interaction is plausible, you need to understand what mTOR does when you train.
When you perform resistance exercise or any meaningful physical effort, your muscles are stressed. That stress triggers a cascade of molecular signaling, and mTORC1 sits at a central node: it upregulates muscle protein synthesis, promotes satellite cell activation (the precursors to new muscle tissue), and drives the tissue repair that makes you stronger.
Rapamycin inhibits mTORC1 directly. That is the mechanism behind its longevity effects — suppressed mTORC1 shifts cells from growth mode toward maintenance and autophagy, which appears to slow age-related damage in animal models. But it is the same mTORC1 that your muscle tissue needs to adapt to training.
This is not a side effect or an unintended consequence. It is the same pathway, doing two different useful things, that rapamycin is selectively dampening.
The weekly dosing strategy used by most longevity physicians is partly designed around this tension. By spacing doses weekly rather than daily, the goal is to allow mTOR to return to baseline activity for most of the week — theoretically reducing the interference with recovery and adaptation. RAPA-EX-01 used weekly dosing and still found blunting, though it cannot tell us whether more frequent dosing would produce a larger effect.
What This Trial Does Not Tell You
Before adjusting your protocol based on this data, the limitations deserve explicit attention.
Population mismatch. The participants were sedentary adults aged 65–85. Their baseline mTOR signaling, muscle mass, hormonal environment, and training response are fundamentally different from a 35-year-old who lifts four days a week. Older, sedentary adults are both more dependent on mTOR activation for training adaptations (they have less margin) and more likely to show measurable effects from any interference. Whether this finding generalizes to a trained, younger cohort is not answerable from this data.
Sample size. Forty participants is enough to detect large effects, but the non-significant trends in 6MWT and grip strength illustrate the limitation: this trial may have been underpowered to detect smaller but real differences in those measures. Conversely, the positive finding on chair stands in a population with n=40 is real signal, but effect size estimates from small trials tend to be inflated.
Exercise type. Chair stands and cycling are functional endurance-oriented movements. They are good proxies for activities of daily living in older adults, but they are not resistance training in the sense that most biohackers mean. Hypertrophy-focused training, progressive overload, and compound lifts engage mTORC1 differently and over different timescales.
Dose context. At 6 mg weekly, participants were at the higher end of what longevity physicians typically prescribe. Some protocols use 3–5 mg weekly or biweekly. Whether the blunting effect scales linearly with dose is not established.
This trial found one serious infection in the rapamycin group. While a single event in a trial of 20 participants per arm is difficult to interpret statistically, it is a reminder that even low-dose rapamycin carries real immunosuppressive risk — particularly under the physical stress of a training program. This is not a supplement with a benign safety profile.
What the Research Community Is Exploring
RAPA-EX-01 raises a question the field has been circling for years: is there a dosing or timing strategy that preserves the longevity benefits of mTOR inhibition while minimizing interference with training adaptations?
A few directions researchers and longevity physicians are actively discussing — not established protocols, but hypotheses being explored:
Post-exercise timing. The idea is to take rapamycin after the acute mTOR activation window from training has passed, rather than before. mTORC1 activity following resistance training peaks in the first several hours and returns toward baseline within 24–48 hours in trained individuals. Whether dosing at day 2 or 3 post-training preserves adaptation while still providing systemic mTOR inhibition is untested in a controlled trial.
Biweekly dosing. Some physicians have moved to every-two-week dosing, which may provide a longer window for unimpeded mTOR signaling. The tradeoff is less cumulative mTOR inhibition, potentially reducing longevity benefit.
Training phase periodization. One theoretical approach is cycling rapamycin use: taking it during periods that are already lower in training volume (deload weeks, off-seasons) and pausing it during focused training blocks. This is a reasonable hypothesis. There is no human RCT testing it.
These are directions the research community is exploring — not recommendations. Any change to a rapamycin protocol requires discussion with the prescribing physician.
How to Track This in Prova
If you are currently taking rapamycin and training, RAPA-EX-01 gives you a concrete reason to run a structured self-experiment rather than guessing.
The trial measured functional outcomes that are fully trackable without a lab: chair-stand repetitions, 6MWT, grip strength, and subjective recovery quality. These map directly to what you can log in Prova.
A 4–8 week on/off tracking protocol might look like this:
- Chair-stand reps: Timed test — how many full stands from a standard chair in 30 seconds. Log weekly, same time of day, same chair.
- Grip dynamometer: Dominant hand, three trials, best result. Available as a cheap ($20–$30) hand dynamometer. Log weekly.
- HRV trend: Morning resting HRV from your wearable. A declining trend during rapamycin phases relative to off phases may suggest impaired recovery, though many variables confound this.
- RPE (Rate of Perceived Exertion): Log your RPE for the same workout sessions — same movement, same load, same sets. If the same effort feels harder during rapamycin weeks, that is signal worth tracking.
- Recovery score: Subjective 1–10 next-day soreness and energy rating, logged at the same time each morning.
Run this for 4–8 weeks with rapamycin, then compare to an equal period without (or a period before you started). The RAPA-EX-01 trial ran 13 weeks — if you are seeing real blunting, 8 weeks of data should surface a trend.
A clean self-experiment here needs one controlled variable: everything else — training load, sleep, nutrition, stress — should be as consistent as possible between comparison periods. If you increase training volume during the on-rapa phase, any change in performance is uninterpretable. Prova's experiment builder can help you structure the protocol and flag confounds in the log.
Be the first to try Prova
We're building an app to track whether rapamycin-exercise actually works. Join the waitlist.
The Bottom Line
RAPA-EX-01 is the first direct human RCT to test rapamycin alongside an exercise program. It found that weekly 6 mg sirolimus may attenuate functional fitness gains in older sedentary adults over 13 weeks — specifically, a statistically significant difference in chair-stand performance, with trends in the same direction for walking distance and grip strength that did not reach significance.
This does not mean rapamycin "destroys gains" or that the two interventions cannot be stacked. It means the theoretical conflict between mTOR inhibition and exercise adaptation showed up as a measurable signal in this specific population, at this dose, over this duration.
What the trial cannot tell you is whether the same effect appears in trained adults in their 30s and 40s — the population most actively experimenting with rapamycin for longevity. That remains an open question. The honest answer right now is: it might, and you should track for it.
For the broader rapamycin story — mechanism, animal data, what the PEARL trial found about immune aging — see our rapamycin longevity overview. For how the PEARL trial results compared to prior expectation, see our PEARL trial breakdown. And if you are weighing rapamycin against other longevity interventions with exercise interaction data, our metformin overview covers a compound with a different mechanism but a similar overlap question.